Systemic therapy of non-cancer conditions, using monoclonal antibody rituximab

#Rituximab is an anti-CD20 monoclonal antibody medication used to treat some oncology diseases (B-cell non-Hodgkin's lymphoma, B-cell chronic lymphocytic leukemia etc) and autoimmune disorders.

It targets and helps the immune system destroy B-cells, which are a type of white blood cells.

Rituximab is approved for several non-cancer conditions, primarily severe autoimmune diseases, where B-cells play a key role in causing inflammation and tissue damage.

In these disorders, rituximab works by targeting and depleting B-lymphocytes that express the #CD20 surface protein.

Examples:

rheumatoid arthritis (RA): in combination with methotrexate, rituximab is used to treat adults with moderate to severe active RA who have not adequately responded to other medications.

immune thrombocytopenia: an immune-mediated bleeding disorder characterized by low platelet counts,

autoimmune hemolytic anemia,

- thrombotic thrombocytopenic purpura: a serious disorder involving blood clotting in small vessels,

systemic lupus erythematosus: some patients with specific organ involvement, like lupus-nephritis, may benefit,

Sjögren's syndrome,

- autoimmune encephalitis: it can be used as a second-line therapy for various forms, especially for patients not responding to initial treatments.

_

For appointments: Telegram-chat 016 669 676 (text message during working hrs).

_

#cambodia #phnompenh #thrombocytopenia #rheumatoidarthritis #lupus #autoimmunehemolyticanemia #Sjögrensyndrome #hospital #monoclonalantibody #bloodtests #hematology #oncology #oncologist